Maven Securities’s Nurix Therapeutics NRIX Stock Holding History

Maven Securities’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30,000	Closed	-$569K	–	505
2025 Q4	$569K	Buy	+30,000	New	+$431K	0.01%	424

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Maven Securities's NRIX Position: Q1 2026 in Review

Maven Securities sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 30,000 shares — an estimated $569K sold.

Maven Securities first reported a position in NRIX in Q4 2025 and held it in 1 quarter. The position peaked at $569K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Maven Securities reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
Maven Securities sold 30,000 Nurix Therapeutics shares in Q1 2026, an estimated $569K.
Maven Securities first reported a position in Nurix Therapeutics in Q4 2025 and held it in 1 quarter.
Maven Securities's Nurix Therapeutics position peaked at $569K in Q4 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.